Rare diseases
Investigational molecules
Locations
Boulevard De Patience Et Beajonc 3 Boite 23, 4000 Liege, Belgium
The organisation demonstrates a focused commitment to advancing diagnostic nuclear medicine and molecular imaging technologies. Their research portfolio encompasses the development and clinical evaluation of novel radiopharmaceutical agents designed to enhance disease detection and characterisation through advanced imaging modalities.
The company's activities reflect a strategic emphasis on translating molecular imaging innovations into clinical practice, with particular attention to optimising radiotracer performance and establishing their utility in diagnostic pathways. This work contributes to the broader field of precision diagnostics through enhanced visualisation of biological processes at the molecular level.
Abscint runs clinical trials in conditions such as Neoplasm malignant, Hormone receptor positive HER2 negative breast cancer, among others.
Clinical trials run by this sponsor – those enrolling participants first.
AustriaIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
